Arthritis medicines and cardiovascular events--"house of coxibs".

@article{Topol2005ArthritisMA,
  title={Arthritis medicines and cardiovascular events--"house of coxibs".},
  author={Eric J. Topol},
  journal={JAMA},
  year={2005},
  volume={293 3},
  pages={
          366-8
        }
}
PHYSICIANS, PATIENTS, AND THE GENERAL PUBLIC ARE confronted with an acute confusional state regarding the cardiovascular safety of medicines for arthritis. Since September 30, 2004, the day that rofecoxib was precipitously withdrawn, there has hardly been a day without significant news on the general topic of cyclooxygenase 2 (COX-2) inhibitors. On December 9, 2004, the US Food and Drug Administration (FDA) issued a black box warning for valdecoxib for life-threatening skin reactions and… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS

Ibuprofen: pharmacology, efficacy and safety

  • Inflammopharmacology
  • 2009
VIEW 6 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Fifty years since the discovery of ibuprofen

  • Inflammopharmacology
  • 2011
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

Drug trial finds big health risks in 2nd painkiller

G. Harris
  • New York Times. December
  • 2004
VIEW 1 EXCERPT

Failing the public health--rofecoxib, Merck, and the FDA.

  • The New England journal of medicine
  • 2004
VIEW 1 EXCERPT

Regulation redefined: the FDA shifts focus; at FDA strong drug ties and less monitoring

G Harris, J. Schwartz
  • New York Times. December
  • 2004
VIEW 1 EXCERPT

Similar Papers